[
    [
        {
            "time": "",
            "original_text": "国盛证券维持泰格医药买入评级：业绩超预期，订单充足成长确定性强",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩超预期",
                    "订单充足",
                    "成长确定性"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券维持泰格医药买入评级：业绩超预期，订单充足成长确定性强",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "群益证券给予泰格医药买进评级：Q1净利润同比增长79%，主业恢复显着,投资收益增厚净利润",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Q1净利润",
                    "同比增长79%",
                    "主业恢复",
                    "投资收益"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "群益证券给予泰格医药买进评级：Q1净利润同比增长79%，主业恢复显着,投资收益增厚净利润",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "会议 | 大湾区(广州)生物医药创新者峰会",
            "features": {
                "keywords": [
                    "大湾区",
                    "生物医药",
                    "创新者峰会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "会议 | 大湾区(广州)生物医药创新者峰会",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "这些讨论干货满满！决定中国创新药产业未来的核⼼竞争力是什么？",
            "features": {
                "keywords": [
                    "创新药",
                    "核心竞争力",
                    "未来"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "这些讨论干货满满！决定中国创新药产业未来的核⼼竞争力是什么？",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "泰格医药一季度营利双涨，净利润同比增长178.62%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "一季度",
                    "营利双涨",
                    "净利润增长178.62%"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药一季度营利双涨，净利润同比增长178.62%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(03347.HK)首季多赚79%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "首季",
                    "多赚79%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)首季多赚79%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港股盘前必读：港交所承认正研究SPAC上市机制最快在6月底前咨询市场",
            "features": {
                "keywords": [
                    "港股",
                    "港交所",
                    "SPAC",
                    "上市机制",
                    "6月底前"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股盘前必读：港交所承认正研究SPAC上市机制最快在6月底前咨询市场",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]